These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 19036704)

  • 1. RUNX1/AML1 DNA-binding domain and ETO/MTG8 NHR2-dimerization domain are critical to AML1-ETO9a leukemogenesis.
    Yan M; Ahn EY; Hiebert SW; Zhang DE
    Blood; 2009 Jan; 113(4):883-6. PubMed ID: 19036704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis.
    Ahn EY; Yan M; Malakhova OA; Lo MC; Boyapati A; Ommen HB; Hines R; Hokland P; Zhang DE
    Proc Natl Acad Sci U S A; 2008 Nov; 105(44):17103-8. PubMed ID: 18952841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis.
    Yan M; Kanbe E; Peterson LF; Boyapati A; Miao Y; Wang Y; Chen IM; Chen Z; Rowley JD; Willman CL; Zhang DE
    Nat Med; 2006 Aug; 12(8):945-9. PubMed ID: 16892037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compatibility of RUNX1/ETO fusion protein modules driving CD34+ human progenitor cell expansion.
    Chen-Wichmann L; Shvartsman M; Preiss C; Hockings C; Windisch R; Redondo Monte E; Leubolt G; Spiekermann K; Lausen J; Brendel C; Grez M; Greif PA; Wichmann C
    Oncogene; 2019 Jan; 38(2):261-272. PubMed ID: 30093631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis.
    Sun XJ; Wang Z; Wang L; Jiang Y; Kost N; Soong TD; Chen WY; Tang Z; Nakadai T; Elemento O; Fischle W; Melnick A; Patel DJ; Nimer SD; Roeder RG
    Nature; 2013 Aug; 500(7460):93-7. PubMed ID: 23812588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulation of CD200R1 in lineage-negative leukemic cells is characteristic of AML1-ETO-positive leukemia in mice.
    Kagiyama Y; Kitaura J; Togami K; Uchida T; Inoue D; Matsukawa T; Izawa K; Kawabata KC; Komeno Y; Oki T; Nakahara F; Sato K; Aburatani H; Kitamura T
    Int J Hematol; 2012 Nov; 96(5):638-48. PubMed ID: 23097187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-sites cleavage of leukemogenic AML1-ETO fusion protein by caspase-3 and its contribution to increased apoptotic sensitivity.
    Lu Y; Peng ZG; Yuan TT; Yin QQ; Xia L; Chen GQ
    Leukemia; 2008 Feb; 22(2):378-86. PubMed ID: 17989718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attenuation of AML1-ETO cellular dysregulation correlates with increased leukemogenic potential.
    DeKelver RC; Yan M; Ahn EY; Shia WJ; Speck NA; Zhang DE
    Blood; 2013 May; 121(18):3714-7. PubMed ID: 23426948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure of the AML1-ETO NHR3-PKA(RIIα) complex and its contribution to AML1-ETO activity.
    Corpora T; Roudaia L; Oo ZM; Chen W; Manuylova E; Cai X; Chen MJ; Cierpicki T; Speck NA; Bushweller JH
    J Mol Biol; 2010 Sep; 402(3):560-77. PubMed ID: 20708017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development.
    Yan M; Burel SA; Peterson LF; Kanbe E; Iwasaki H; Boyapati A; Hines R; Akashi K; Zhang DE
    Proc Natl Acad Sci U S A; 2004 Dec; 101(49):17186-91. PubMed ID: 15569932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RUNX1-ETO induces a type I interferon response which negatively effects t(8;21)-induced increased self-renewal and leukemia development.
    DeKelver RC; Lewin B; Weng S; Yan M; Biggs J; Zhang DE
    Leuk Lymphoma; 2014 Apr; 55(4):884-91. PubMed ID: 23772668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ETO, but not leukemogenic fusion protein AML1/ETO, augments RBP-Jkappa/SHARP-mediated repression of notch target genes.
    Salat D; Liefke R; Wiedenmann J; Borggrefe T; Oswald F
    Mol Cell Biol; 2008 May; 28(10):3502-12. PubMed ID: 18332109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure of the AML1-ETO eTAFH domain-HEB peptide complex and its contribution to AML1-ETO activity.
    Park S; Chen W; Cierpicki T; Tonelli M; Cai X; Speck NA; Bushweller JH
    Blood; 2009 Apr; 113(15):3558-67. PubMed ID: 19204326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Drosophila model identifies calpains as modulators of the human leukemogenic fusion protein AML1-ETO.
    Osman D; Gobert V; Ponthan F; Heidenreich O; Haenlin M; Waltzer L
    Proc Natl Acad Sci U S A; 2009 Jul; 106(29):12043-8. PubMed ID: 19581587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells.
    Wichmann C; Chen L; Heinrich M; Baus D; Pfitzner E; Zörnig M; Ottmann OG; Grez M
    Cancer Res; 2007 Mar; 67(5):2280-9. PubMed ID: 17332359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice.
    Schessl C; Rawat VP; Cusan M; Deshpande A; Kohl TM; Rosten PM; Spiekermann K; Humphries RK; Schnittger S; Kern W; Hiddemann W; Quintanilla-Martinez L; Bohlander SK; Feuring-Buske M; Buske C
    J Clin Invest; 2005 Aug; 115(8):2159-68. PubMed ID: 16025155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the nuclear distribution of the translocation t(8;21)-derived fusion protein AML1/ETO by confocal laser scanning microscopy.
    Nagel S; Hambach L; Krauter J; Venturini L; Heidenreich O; Ganser A; Heil G
    J Hematother Stem Cell Res; 2002 Apr; 11(2):401-8. PubMed ID: 11983111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cooperation between RUNX1-ETO9a and novel transcriptional partner KLF6 in upregulation of Alox5 in acute myeloid leukemia.
    DeKelver RC; Lewin B; Lam K; Komeno Y; Yan M; Rundle C; Lo MC; Zhang DE
    PLoS Genet; 2013; 9(10):e1003765. PubMed ID: 24130502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The AML1-MTG8 leukemic fusion protein forms a complex with a novel member of the MTG8(ETO/CDR) family, MTGR1.
    Kitabayashi I; Ida K; Morohoshi F; Yokoyama A; Mitsuhashi N; Shimizu K; Nomura N; Hayashi Y; Ohki M
    Mol Cell Biol; 1998 Feb; 18(2):846-58. PubMed ID: 9447981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
    Lo Coco F; Pisegna S; Diverio D
    Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.